MedTrace Logo

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

NCT05674695 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2023-01-06

No results posted yet for this study

Summary

The Spanish Registry of Systemic therapy in atopic eczema, BIOBADATOP, assesses drug safety and treatment effectiveness as well as treatment impact on quality of life in children and adults with atopic eczema receiving systemic immuno-modulatory therapies in Spanish daily practice.

The main objectives are:

1. To assess short and long-term safety of systemic therapies (including phototherapy) for atopic eczema (pharmacovigilance).
2. To assess short and long-term effectiveness of systemic therapies, providing a basis for shared decision making and guidelines.

Secondary objectives are:

1. To assess short and long-term safety of topical therapies for atopic eczema.
2. To assess effectiveness of different methods of care, including patient training.
3. To describe atopic dermatitis comorbidities.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Ciclosporin

Any systemic drug used for atopic dermatitis in clinical practice

Sponsors & Collaborators

  • Fundación Academia Española de Dermatología

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2029-01-01
Completion
2029-01-01
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05674695 on ClinicalTrials.gov